A Most Memorable Hockey Tribute Happened in Columbus Last Night
That Nate Silver Trendline Is Not Good News for Kamala
How Pelosi Responds When Asked If She Thought Biden Has Forgiven Her
Joe Biden Tried to Attack Trump. He Only Showed He's Mentally Cooked.
'Adios Michigan': Kamala Fails to Secure Another Key Endorsement
Harris' Town Hall Event With Charlamagne Got Roasted in the Comments
DeSantis Announces Update to Viral Video of Highway Patrol Rescuing Dog Abandoned as...
Georgia Judge Blocks Ballot Hand Counting Rule
Why This Average American Is Voting for Donald Trump…Again
Dems in Disarray: AOC and Fetterman Fighting Online Over Israel
Did You Notice Anything Odd at the Victoria's Secret Fashion Show?
Reality Again Debunks the Left's Ugly Lies and Misinformation About Georgia's Election Law
U.S. Army Training Materials Labeled Pro-Life Groups As Terrorists, Lawsuit Says
Catholic Group Doesn’t Buy Whitmer’s Apology for Stunt Mocking Catholics
Biden Administration Chooses Politics Over National Security and Norms
Tipsheet

FDA Authorizes COVID-19 Booster for Ages 5 to 11

AP Photo/Ted Jackson

On Tuesday, the U.S. Food and Drug Administration (FDA) authorized a booster dose of the Pfizer-BioNTech COVID-19 vaccine for children ages 5 to 11. 

The FDA published a news release on Tuesday explaining how the single-use booster can be administered to children in this age group at least five months after their primary two-dose vaccine.

Advertisement

“Since authorizing the vaccine for children down to 5 years of age in October 2021, emerging data suggest that vaccine effectiveness against COVID-19 wanes after the second dose of the vaccine in all authorized populations. The FDA has determined that the known and potential benefits of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age at least five months after completing a primary series outweigh its known and potential risks and that a booster dose can help provide continued protection against COVID-19 in this and older age groups,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, in the release.

Townhall covered in December that the FDA authorized the Pfizer booster for 16 and 17 year olds as the Delta variant spread and the Omicron variant emerged. In early January, the FDA authorized a booster shot for children 12 through 15 years of age.

The release noted that the booster dose for 5 to 11 year olds was assessed in about 400 children five to nine months after they received their primary vaccine dosage. The most common side effects were pain, redness, swelling, fatigue, headache, muscle and joint pains, chills and fever. 

Advertisement

This age demographic is the youngest to date to receive authorization from the FDA for a COVID-19 booster shot. In February, Townhall reported how Pfizer and BioNTech were testing a third dose of the vaccine, following “disappointing” results from the two-shot regime in children under 5. Shortly after, Pfizer announced it was delaying the application process for Emergency Use Authorization for their vaccine for children ages 6 months through 4 years.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement